MLTX - MoonLake Immunotherapeutics News

HC Wainwright & Co. Maintains Buy on MoonLake, Raises Price Target to $50

HC Wainwright & Co. analyst Raghuram Selvaraju maintains MoonLake (NASDAQ:MLTX) with a Buy an

MoonLake Immunotherapeutics Target of Unusually High Options Trading (NASDAQ:MLTX)

MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report) was the recipient of some unusual optio

MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study

MoonLake Immunotherapeutics (MLTX) announces positive Phase 3 psoriatic arthritis trial results. Cas

reuters.com

MoonLake's psoriatic arthritis drug meets key goals in late-stage trial

MoonLake Immunotherapeutics said on Monday its experimental drug met all main goals in a late-stage

MoonLake Immunotherapeutics Reports Topline Results From Phase 3 IZAR-1 Trial Showing Sonelokimab Me

Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokim

MoonLake Q2 EPS $(0.84) Beats $(0.93) Estimate

MoonLake (NASDAQ:MLTX) reported quarterly losses of $(0.84) per share which beat the analyst consens

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriati

Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokim

Arrowstreet Capital Limited Partnership Acquires New Shares in MoonLake Immunotherapeutics $MLTX

Arrowstreet Capital Limited Partnership bought a new stake in MoonLake Immunotherapeutics (NASDAQ: M

zacks.com

Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This H

The consensus price target hints at a 73.4% upside potential for MOONLAKE IMMUNO (MLTX). While empir

HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $45 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:MLTX) with a Buy a

MoonLake Immunotherapeutics' CFO Sells 39K Shares

This clinical-stage biotech focused on Nanobody therapies reported a notable insider sale.

Leerink Partners Maintains Outperform on MoonLake, Raises Price Target to $29

Leerink Partners analyst Thomas Smith maintains MoonLake (NASDAQ:MLTX) with a Outperform and rais

seekingalpha.com

MoonLake: 'Buy' Sonelokimab BLA Submission HS September And Label Expansion

MoonLake Immunotherapeutics maintains a Buy rating, supported by positive FDA interactions and stron

Why MoonLake Immunotherapeutics Stock Wilted on Wednesday

It aims to raise up to $200 million in the offering. This will support its efforts to bring its top

FedEx, Cerebras Systems And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

U.S. stock futures mixed, Nasdaq 100 up 100 points. FedEx falls after Q4 results, beating estimates

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

ZUG, Switzerland, June 23, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinica

seekingalpha.com

MoonLake Immunotherapeutics: Label Upside Drives The Next Leg Higher

MoonLake Immunotherapeutics is positioned for upside on differentiated efficacy and a large, underpe

MoonLake Immunotherapeutics Announces Proposed Public Offering Of $150M Of Its Class A Ordinary Shar

MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake"), a clinical-stage biotechnology compa

MoonLake Immunotherapeutics Announces Proposed Public Offering

ZUG, Switzerland, June 22, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinica

seekingalpha.com

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On

U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Thera

Why Is MoonLake Immunotherapeutics Stock Soaring Monday?

MoonLake reported durable one-year Phase 3 hidradenitis suppurativa data for sonelokimab and plans a

Why Sagtec Global Shares Are Trading Higher By Around 76%; Here Are 20 Stocks Moving Premarket

SAGTEC GLOBAL (NASDAQ: SAGT) gained 75.6% in pre-market trading after projecting 35% revenue growth

Reported Sunday, MoonLake Announces Phase 3 VELA Program Week 52 Results Showing 67.2% Of Sonelokima

Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradeni

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Supp

ZUG, Switzerland, June 21, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (MoonLake or the Compan

HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $45 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:MLTX) with a Buy a

MoonLake Immunotherapeutics CFO Trims His Stake. Should Investors Be Concerned?

This clinical-stage biotech focused on inflammatory diseases reported a notable insider sale amid a

Moonlake Immunotherapeutics Inks Master Commercial Supply Agreement With Vetter Pharma To Manufactur

On May 22, 2026, MoonLake Immunotherapeutics (the "Company") entered into a Master Commercia

Needham Maintains Buy on MoonLake, Raises Price Target to $30

Needham analyst Serge Belanger maintains MoonLake (NASDAQ:MLTX) with a Buy and raises the price t

FDA Aligns With MoonLake On Lead Drug Submission Plans, Stock Soars

MoonLake Immunotherapeutics (NASDAQ:MLTX) shares are up during Monday's trading session, trading hig

FDA Aligns With MoonLake On Lead Drug Submission Plans, Stock Soars

MoonLake shares climbed after positive FDA pre-BLA feedback for sonelokimab, while analysts maintain

investors.com

MoonLake Clears A Key Regulatory Hurdle, And Shares Rocket

Shares of MoonLake Immunotherapeutics bounded higher Monday after the biotech said it met with the F

HC Wainwright & Co. Maintains Buy on MoonLake, Raises Price Target to $45

HC Wainwright & Co. analyst Raghuram Selvaraju maintains MoonLake (NASDAQ:MLTX) with a Buy an

Reported Sunday, MoonLake Secures FDA Alignment On Sonelokimab BLA Submission Plan, Holds $357.9M Ca

MoonLake conducted a positive final pre-BLA (Biologics License Application) meeting with the U.S. Fo

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S.

ZUG, Switzerland, May 10, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake” or the “Comp

The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the

CEO Jorge Santos da Silva sold 150,000 shares for a transaction value of approximately ~$2.75 millio

Da Silva Jorge Santos Sells 98,127 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock

MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report) CEO Da Silva Jorge Santos sold 98,127 s

MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 6% – Should You Sell?

MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report)'s share price traded down 6% during mid

Insmed Drug Misses Primary Goal, Program Axed

Insmed halts HS program after CEDAR study miss; analysts cite trial challenges while focus shifts to

MoonLake Says Lead Drug Shows Durable Response, Eyes FDA Filing

MoonLake shares fluctuate as Phase 3 HS data show 62% HiSCR75 response at Week 40; FDA feedback supp

Reported Saturday, MoonLake's Phase 3 VELA Trials Show Sonelokimab Achieves 62% HiSCR75 And Up To 32

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppura

This APA Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Monday

Top Wall Street analysts upgraded APA Corp. & MoonLake Immunotherapeutics, see why & what ot

Wolfe Research Upgrades MoonLake to Outperform, Raises Price Target to $24

Wolfe Research analyst Andy Chen upgrades MoonLake (NASDAQ:MLTX) from Underperform to Outperform

Rothschild & Co Upgrades MoonLake to Buy, Raises Price Target to $40

Rothschild & Co analyst Qize Ding upgrades MoonLake (NASDAQ:MLTX) from Neutral to Buy and rai

Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on top names. See all changes on analyst ratings page

Clear Street Maintains Buy on MoonLake, Raises Price Target to $70

Clear Street analyst Kaveri Pohlman maintains MoonLake (NASDAQ:MLTX) with a Buy and raises the pr

RBC Capital Maintains Sector Perform on MoonLake, Raises Price Target to $13

RBC Capital analyst Brian Abrahams maintains MoonLake (NASDAQ:MLTX) with a Sector Perform and rai

HC Wainwright & Co. Maintains Buy on MoonLake, Raises Price Target to $40

HC Wainwright & Co. analyst Raghuram Selvaraju maintains MoonLake (NASDAQ:MLTX) with a Buy an

Oppenheimer Maintains Outperform on MoonLake, Raises Price Target to $35

Oppenheimer analyst Andreas Argyrides maintains MoonLake (NASDAQ:MLTX) with a Outperform and rais